View Main Condition: Lung Cancer
Ravi Salgia is an Oncologist in Newport Beach, California. Salgia has been practicing medicine for over 38 years and is rated as an Elite expert by MediFind in the treatment of Small Cell Lung Cancer (SCLC). He is also highly rated in 25 other conditions, according to our data. His top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NCSLC), Small Cell Lung Cancer (SCLC), Tissue Biopsy, and Gamma Knife Radiosurgery.
Neal Ready is an Oncologist in Durham, North Carolina. Ready has been practicing medicine for over 37 years and is rated as an Elite expert by MediFind in the treatment of Small Cell Lung Cancer (SCLC). He is also highly rated in 21 other conditions, according to our data. His top areas of expertise are Small Cell Lung Cancer (SCLC), Lung Cancer, Non-Small Cell Lung Cancer (NCSLC), Large-Cell Lung Carcinoma, and Gamma Knife Radiosurgery. Ready is currently accepting new patients.
Martin Edelman is an Oncologist and a Hematologist Oncology expert in Philadelphia, Pennsylvania. Edelman has been practicing medicine for over 41 years and is rated as an Elite expert by MediFind in the treatment of Small Cell Lung Cancer (SCLC). He is also highly rated in 12 other conditions, according to our data. His top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NCSLC), Squamous Cell Lung Carcinoma, Small Cell Lung Cancer (SCLC), and Gamma Knife Radiosurgery. Edelman is currently accepting new patients.
Summary: Phase 2, multicenter, single-arm, open-label basket study designed to evaluate the safety and efficacy of milademetan in patients with advanced or metastatic solid tumors refractory or intolerant to standard-of-care therapy that exhibit wild-type (WT) TP53 and MDM2 copy number (CN) ≥ 8 using prespecified biomarker criteria.
Summary: PT217 is a bispecific antibody (bsAb) against human DLL3 (huDLL3) and human CD47 (huCD47). This is an open label, Phase I study to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary efficacy of PT217 in subjects with advanced or refractory cancers. Patients with the following tumor types will be eligible for screening: unresectable or small cell lung cancer (SCLC), large cell...